Eli Lilly reported second-quarter revenue growth of 48%, powered by its GLP-1 drugs Mounjaro and Zepbound, which treat Type 2 diabetes and obesity. The company beat consensus earnings estimates for the quarter and followed that with a guidance raise, lifting its 2026 revenue outlook to a range of $85 billion to $87 billion, up from the prior range of $82 billion to $85 billion. The midpoint of that new range represents a $2.5 billion increase in expected annual revenue.
Lilly is the largest pure-play GLP-1 name by market cap, so its guidance raise sets the tone for the entire obesity drug sector, including competitors and adjacent suppliers. Investors holding LLY directly get a fundamental catalyst that supports the current premium valuation. Broader healthcare ETFs with significant Lilly weightings will also see upward pressure.
August 2025: Novo Nordisk Q2 earnings report (date to be confirmed by company). Next FDA decision windows on GLP-1 label expansions are tracked quarterly. LLY next earnings: approximately late October 2025.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block, and the live update timeline (2 updates so far).
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief